vs
GENMAB A/S（GMAB）与RANGE RESOURCES CORP（RRC）财务数据对比。点击上方公司名可切换其他公司
GENMAB A/S的季度营收约是RANGE RESOURCES CORP的1.2倍（$925.0M vs $786.9M），GENMAB A/S净利率更高（36.3% vs 22.8%，领先13.6%），GENMAB A/S同比增速更快（18.7% vs 18.0%）
Genmab A/S是丹麦生物技术企业，1999年2月由原BankInvest生物医药风险基金董事总经理Florian Schönharting创立，总部位于丹麦哥本哈根，在荷兰乌得勒支、美国新泽西州普林斯顿、日本东京、德国慕尼黑及中国苏州均设有子公司，深耕生物科技领域的研发与运营。
Range Resources Corporation是一家总部位于美国得克萨斯州沃斯堡的天然气勘探开采企业，核心运营区域为马塞勒斯页岩地层，是该地区拥有土地面积最大的运营商，专注于天然气资源的勘探、开发与生产业务，在北美油气开发领域具备深厚的行业积累。
GMAB vs RRC — 直观对比
营收规模更大
GMAB
是对方的1.2倍
$786.9M
营收增速更快
GMAB
高出0.8%
18.0%
净利率更高
GMAB
高出13.6%
22.8%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $925.0M | $786.9M |
| 净利润 | $336.0M | $179.1M |
| 毛利率 | 93.8% | 94.5% |
| 营业利润率 | 38.9% | — |
| 净利率 | 36.3% | 22.8% |
| 营收同比 | 18.7% | 18.0% |
| 净利润同比 | 65.5% | 88.8% |
| 每股收益（稀释后） | $5.42 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GMABRRC
| Q4 25 | — | $786.9M | ||
| Q3 25 | — | $655.3M | ||
| Q2 25 | $925.0M | $699.6M | ||
| Q1 25 | — | $846.3M | ||
| Q4 24 | — | $667.0M | ||
| Q3 24 | — | $567.9M | ||
| Q2 24 | $779.0M | $513.2M | ||
| Q1 24 | — | $598.8M |
净利润GMABRRC
| Q4 25 | — | $179.1M | ||
| Q3 25 | — | $144.3M | ||
| Q2 25 | $336.0M | $237.6M | ||
| Q1 25 | — | $97.1M | ||
| Q4 24 | — | $94.8M | ||
| Q3 24 | — | $50.7M | ||
| Q2 24 | $203.0M | $28.7M | ||
| Q1 24 | — | $92.1M |
毛利率GMABRRC
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | 93.8% | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | 96.4% | 93.4% | ||
| Q1 24 | — | 94.7% |
营业利润率GMABRRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 38.9% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 30.3% | — | ||
| Q1 24 | — | — |
净利率GMABRRC
| Q4 25 | — | 22.8% | ||
| Q3 25 | — | 22.0% | ||
| Q2 25 | 36.3% | 34.0% | ||
| Q1 25 | — | 11.5% | ||
| Q4 24 | — | 14.2% | ||
| Q3 24 | — | 8.9% | ||
| Q2 24 | 26.1% | 5.6% | ||
| Q1 24 | — | 15.4% |
每股收益（稀释后）GMABRRC
| Q4 25 | — | $0.75 | ||
| Q3 25 | — | $0.60 | ||
| Q2 25 | $5.42 | $0.99 | ||
| Q1 25 | — | $0.40 | ||
| Q4 24 | — | $0.38 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | $3.13 | $0.12 | ||
| Q1 24 | — | $0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $204.0K |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $5.3B | $4.3B |
| 总资产 | $6.5B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
现金及短期投资GMABRRC
| Q4 25 | — | $204.0K | ||
| Q3 25 | — | $175.0K | ||
| Q2 25 | $1.3B | $134.0K | ||
| Q1 25 | — | $344.6M | ||
| Q4 24 | — | $304.5M | ||
| Q3 24 | — | $277.4M | ||
| Q2 24 | $622.0M | $251.1M | ||
| Q1 24 | — | $343.1M |
总债务GMABRRC
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | — | $1.7B | ||
| Q2 24 | — | $1.7B | ||
| Q1 24 | — | $1.8B |
股东权益GMABRRC
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.2B | ||
| Q2 25 | $5.3B | $4.1B | ||
| Q1 25 | — | $3.9B | ||
| Q4 24 | — | $3.9B | ||
| Q3 24 | — | $3.9B | ||
| Q2 24 | $4.4B | $3.9B | ||
| Q1 24 | — | $3.8B |
总资产GMABRRC
| Q4 25 | — | $7.4B | ||
| Q3 25 | — | $7.2B | ||
| Q2 25 | $6.5B | $7.1B | ||
| Q1 25 | — | $7.4B | ||
| Q4 24 | — | $7.3B | ||
| Q3 24 | — | $7.2B | ||
| Q2 24 | $5.6B | $7.3B | ||
| Q1 24 | — | $7.4B |
负债/权益比GMABRRC
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.29× | ||
| Q2 25 | — | 0.29× | ||
| Q1 25 | — | 0.43× | ||
| Q4 24 | — | 0.43× | ||
| Q3 24 | — | 0.44× | ||
| Q2 24 | — | 0.44× | ||
| Q1 24 | — | 0.46× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $349.0M | $257.5M |
| 自由现金流经营现金流 - 资本支出 | $327.0M | — |
| 自由现金流率自由现金流/营收 | 35.4% | — |
| 资本支出强度资本支出/营收 | 2.4% | — |
| 现金转化率经营现金流/净利润 | 1.04× | 1.44× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GMABRRC
| Q4 25 | — | $257.5M | ||
| Q3 25 | — | $247.5M | ||
| Q2 25 | $349.0M | $336.2M | ||
| Q1 25 | — | $330.1M | ||
| Q4 24 | — | $217.9M | ||
| Q3 24 | — | $245.9M | ||
| Q2 24 | $438.0M | $148.8M | ||
| Q1 24 | — | $331.9M |
自由现金流GMABRRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $327.0M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $430.0M | — | ||
| Q1 24 | — | — |
自由现金流率GMABRRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 35.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 55.2% | — | ||
| Q1 24 | — | — |
资本支出强度GMABRRC
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | — | — |
现金转化率GMABRRC
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | 1.04× | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | 2.16× | 5.18× | ||
| Q1 24 | — | 3.60× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GMAB
| Darzalex | $638.0M | 69% |
| Kesimpta | $108.0M | 12% |
| Net Product Sales | $101.0M | 11% |
| Other | $28.0M | 3% |
| Tepezza | $20.0M | 2% |
| Reimbursement Revenue | $13.0M | 1% |
| Bio N Tech | $11.0M | 1% |
| Abb Vie | $5.0M | 1% |
| Milestone Revenue | $1.0M | 0% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
